Table 2.
Release of lutetium‑177- and copper‑64-labeled TATE variants from intact MPC cells
| TATE variant | RN | A m | Fast fraction a | t1/2 (fast) | t1/2 (slow) | 24 h release a | Exp. |
|---|---|---|---|---|---|---|---|
| [MBq/nmol] | [%] | [hours] | [hours] | [%] | n b | ||
| DOTA | 177Lu | 37.9 ± 7.42 | 39 ± 3.9 | 0.82 ± 0.19 | 68.0 ± 25.1 | 52 ± 1.9 | 4 |
| NODAGA | 64Cu | 44.7 ± 7.98 | 42 ± 3.3 | 0.74 ± 0.13 | 21.4 ± 2.19 † | 73 ± 1.9 # | 5 |
| NODAGA-cLAB4 | 64Cu | 42.5 ± 9.15 | 45 ± 1.4 | 0.52 ± 0.12 | 20.0 ± 3.44 † | 76 ± 2.0 # | 4 |
(Am) molar activity at incubation start; (RN) radionuclide; a relative loss of radioligand normalized to initial SSTR2-specific binding after exposure to the radioligand (25 nmol/L) for 1 hour; b number of independent experiments (n) each performed in sextuplicate; data presented as means ± standard error; significance of differences compared to [177Lu]Lu‑DOTA-TATE: † p < 0.01, # p < 0.001